Intravenous to Oral (IV:PO) Anti-Infective Conversion Therapy

Quintiliani R. , Cooper B.W. , Nightingale C.H. Economic impact of streamlining antibiotic administration. Am J Med. 1987; 82: 391–394.

Quintiliani R. , Crowe H.M. , Nightingale C.H. Transition antibiotic therapy. Can J Infect Dis. 1995; 6(suppl A): 6A–10A.

Nathwani D. , Tillotson G. , Davey P. Sequential antimicrobial therapy: the role of quinolones. J Antimicrob Chemother. 1997; 39: 441–446. Review.

Ramirez J.A. , Srinath L. , Ahkee S. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995; 155: 1273–1276.

Weingarten S.R. , Riedinger M.S. Varis G, et al. Identification of low-risk hospitalized patients with pneumonia: implications for early conversion to oral antimicrobial therapy. Chest. 1994; 105: 1109–1115.

Ahkee S. , Smith S. , Newman D. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-month prospective study. Pharmacotherapy. 1997; 17: 569–575.

Przybylski K.G. , Rybak M.J. , Martin P.R. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy. 1997; 17: 271–276.

Rimmer D. Third generation cephalosporins in the parenteral to oral switch. Pharmacoeconomics. 1994; 5(suppl 2): 27–33.

Chan R. , Hemeryck L. , O'Regan M. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. Br Med J. 1995; 310: 1360–1362.

Ehrenkranz N.J. , Nerenberg D.E. , Shultz J.M. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol. 1992; 13: 21–32.

Hendrickson J.R. , North D.S. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother. 1995; 29: 561–565.

Paladino J.A. , Sperry H.E. , Backes J.M. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med. 1991; 91: 462–470.

Nicolau D.P. , Quintiliani R. , Nightingale C.H. Antibiotic kinetics and dynamics for the clinician. Med Clin North Am. 1995; 79: 477–495. Review.

Jewesson P.J. Pharmaceutical, pharmacokinetic and other consideration for IV to oral step-down therapy. Can J Infect Dis. 1995; 6: 11A–16A.

Craig W.A. , Ebert S.C. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis. 1991; suppl 74: 63–70.

Quintiliani R. , Nightingale C. Antimicrobials and therapeutic decision making: an historical perspective. Pharmacotherapy. 1991; 11(suppl): 6S–13S.

Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26: 1–12. Review.

Vogelman B. , Craig W.A. Kinetics of antimicrobial activity. J Pediatr. 1986; 108: 835–840.

Craig W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis. 1993; 12(suppl 1): S6–S8. Review.

Schentag J.J. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scand J Infect Dis. 1991; suppl 74: 218–234.

Schentag J. The pharmacoeconomics of treating hospital-acquired pneumonia: developing a rational strategy. Pharmaguide Hosp Med. 1997; 10: 1–12.

Forrest A. , Nix D.E. , Ballow C.H. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37: 1073–1081.

Lettieri J.T. , Rogge M.C. , Kaiser L. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992; 36: 993–996.

Yuk J.H. , Nightingale C.H. , Quintiliani R. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1991; 35: 384–386.

Craig W.A. , Andes D.R. Parenteral versus oral antibiotic therapy. Med Clin North Am. 1995; 79: 497–508. Review.

Klauch B. , Irby D. Implementation of a pharmacist-initiated, automatic intravenous to oral step-down program for antibiotics: preliminary results 1998. Abstract.

Talcott J.A. , Finberg R. , Mayer R.J. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988; 148: 2561–2568.

Talcott J.A. , Siegel R.D. , Finberg R. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992; 10: 316–322.

Davis D.D. , Raebel M.A. Ambulatory management of chemotherapy-induced fever and neutropenia in adult cancer patients. Ann Pharmacother. 1998; 32: 1317–1323. Review.

Rubenstein E.B. , Rolston K. , Benjamin R.S. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993; 71: 3640–3646.

Malik I.A. , Abbas Z. , Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet. 1992; 339: 1092–1096.

Gardembas-Pain M. , Desablens B. , Sensebe L. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol. 1991; 2: 485–487.

Malik I.A. , Khan W.A. , Karim M. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med. 1995; 98: 224–231.

Malik I.A. , Khan W.A. , Aziz Z. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis. 1994; 19: 522–527.

Rolston K. , Rubenstein E. Ambulatory management of febrile episodes in low-risk neutropenic patients. Programs and Proceedings of the 35th Interscience Conference on Antimicrobial Agents in Chemotherapy. San Francisco, Calif; 1995: 333. Abstract.

Hidalgo M. , Hornedo J. , Lumbrerasi C. Ambulatory care of patients with low risk postchemotherapy neutropenic fever with oral ofloxacin: results of a randomized clinical trial. Proc Annu Meet Am Soc Clin Oncol. 1997; 16: A198. Abstract.

Freifeld A. , Marchigiani D. , Walsh T. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999; 341: 305–311.

Cunha B.A. Intravenous-to-oral antibiotic switch therapy: a cost-effective approach. Postgrad Med. 1997; 101: 111–123. Review.

Hitt C.M. , Nightingale C.H. , Quintiliani R. Streamlining antimicrobial therapy for lower respiratory tract infections. Clin Infect Dis. 1997; 24(suppl 2): S231–S237. Review.

Jewesson P.J. Cost-effectiveness and value of an IV switch. Pharmacoeconomics. 1994; 5(suppl 2): 20–26.

Arnow P.M. , Quimosing E.M. , Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis. 1993; 16: 778–784.

Raad I.I. , Bodey G.P. Infectious complications of indwelling vascular catheters. Clin Infect Dis. 1992; 15: 197–208. Review.

Nightingale C.H. , Quintiliani R. Cost of oral antibiotic therapy. Pharmacotherapy. 1997; 17: 302–307.

Frighetto L. , Nickoloff D. , Martinusen S.M. Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Ann Pharmacother. 1992; 26: 1447–1451.

Solomkin J.S. , Reinhare H.H. , Dellinger E.P. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections: the Intra-Abdominal Infection Study Group. Ann Surg. 1996; 223: 303–315.

Cohn S.M. , Cohn K.A. , Rafferty M.J. Enteric absorption of ciprofloxacin during the immediate postoperative period. J Antimicrob Chemother. 1995; 36: 717–721.

Nathwani D. Sequential switch therapy for lower respiratory tract infections: a European perspective. Chest. 1998; 113(suppl 3): 211S–218S.

Louie T.J. Intravenous to oral step-down antibiotic therapy: another cost-effective strategy in an era of shrinking health care dollars. Can J Infect Dis. 1994; 5(suppl C): 45C–50C.

Drug Topics Red Book. 103rd ed. Montvale, NJ: Medical Economics Co; 1999.